Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Christopher Leamon Insider Profile
4 Followers
Christopher Leamon, VP of Research at Endocyte, holds 0.00 shares in Fusion Pharmaceuticals (Ticker: FUSN), holds 0.00 shares in Endocyte (Ticker: ECYT).
Christopher Leamon Endocyte (ECYT)VP of Research
Endocyte (ECYT)
VP of Research
Not Ranked
Christopher Leamon has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Christopher Leamon does not currently own shares as a corporate insider.
A breakdown of Christopher Leamon's holdings
Insider Roles
Christopher Leamon does not currently hold a role as a corporate insider.
Roles that Christopher Leamon holds in companies
Most Profitable Insider Trade
Stock:
Endocyte
(ECYT)
(ECYT)
Rating:Informative Buy
Date:Feb 26, 2015 - Feb 26, 2016
Return:-48.30%
The most profitable trade made by Christopher Leamon
Christopher Leamon's Trading History
Endocyte
Dec 21, 2018
―
Uninformative Sell
3.94M
$0.00
Fusion Pharmaceuticals
Jun 04, 2024
―
Uninformative Sell
―
$0.00
List of latest transactions for each holding click on a transaction to see Christopher Leamon's performance on stock
You May Also Like
Christopher Leamon insider profile FAQ
What is the percentage of profitable transactions made by Christopher Leamon?
The percentage of profitable transactions made by Christopher Leamon is ―.
What is the average return per transaction made by Christopher Leamon?
The average return per transaction made by Christopher Leamon is ―.
What stocks does Christopher Leamon hold?
Christopher Leamon holds: ECYT, FUSN stocks.
What was Christopher Leamon’s latest transaction?
Christopher Leamon latest transaction was an Uninformative Sell of ―.
What was Christopher Leamon's most profitable transaction?
Christopher Leamon’s most profitable transaction was an Informative Buy of ECYT stock on February 26, 2015. The return on the trade was -48.30%.
What is Christopher Leamon's role in Endocyte?
Christopher Leamon's role in Endocyte is VP of Research.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.